ライフサイエンスコーパス: medical treatment

1 plantations (AVIs) and 194 deaths (115 under medical treatment).

2 d reduces ischaemia to a greater extent than medical treatment.

3 4% for both surgical procedures and 15% for medical treatment.

4 iculitis patients do not recur after initial medical treatment.

5 rtery disease who remain symptomatic despite medical treatment.

6 on resolved spontaneously after conservative medical treatment.

7 bout a third of patients remain resistant to medical treatment.

8 itis was diagnosed and the patient was given medical treatment.

9 1.4%, 95% CI -1.9% to -0.9%, P < 0.001) than medical treatment.

10 ents undergoing neurosurgical procedures for medical treatment.

11 t disease; surgical and other complications; medical treatment.

12 in whom testing will have a direct impact on medical treatment.

13 hoice of undergoing surgery or continuing on medical treatment.

14 Most eyes have glaucoma and are on medical treatment.

15 er in patients who do not respond to optimal medical treatment.

16 sponsive to both behavioral modification and medical treatment.

17 in adolescents who do not respond to primary medical treatment.

18 elopment of the earliest recorded systems of medical treatment.

19 o continue to be symptomatic despite maximal medical treatment.

20 for patients nonresponsive after 4 weeks of medical treatment.

21 cutaneous PFO closure and those who received medical treatment.

22 vention), whereas 58 patients remained under medical treatment.

23 ts who underwent percutaneous PFO closure or medical treatment.

24 for immediate revascularization or intensive medical treatment.

25 barrier needs to be overcome for successful medical treatment.

26 selective patients who are noncompliant with medical treatment.

27 th respiratory muscle fatigue and failure of medical treatment.

28 significantly reduced compared with standard medical treatment.

29 enotype, inflammatory status, phenotype, and medical treatment.

30 and reduced ejection fraction under optimal medical treatment.

31 ttent claudication who have not responded to medical treatment.

32 A small minority are refractory to medical treatment.

33 ho could potentially benefit from additional medical treatment.

34 this group of stable patients compared with medical treatment.

35 quality of life higher and to recommend full medical treatment.

36 monstrated equal efficacy of surgical versus medical treatment.

37 D symptoms, although only 28% were receiving medical treatment.

38 with laser peripheral iridotomy and topical medical treatment.

39 edical treatment, or had neither surgery nor medical treatment.

40 l processes and can guide bioremediation and medical treatments.

41 essential in evaluating the effectiveness of medical treatments.

42 utics is an expanding field that can improve medical treatments.

43 of additional mutations, and the effects of medical treatments.

44 is a public health problem without effective medical treatments.

45 ntial applications in tissue engineering and medical treatments.

46 nquiry, giving the hope of syndrome-specific medical treatments.

47 demographics, co-morbidities, and dental and medical treatments.

48 the propagation of misinformation concerning medical treatments.

49 ead to a continuous change of guidelines for medical treatments.

50 tio was $8289 per QALY for trabeculectomy vs medical treatment, $13 896 per QALY for tube insertion v

51 r percutaneous PFO closure (150 patients) or medical treatment (158 patients).

52 All patients received medical treatment, 20 (90.9%) underwent surgery, and 4 (

53 PFO closure (11%) and 22 patients slated to medical treatment (21%; hazard ratio=0.43; 95% confidenc

54 rejecting surgery were fear (37%), preferred medical treatment (27 %) and cost (15 %).

55 erature review, 54 (96.4%) patients received medical treatment, 51 (91.1%) underwent surgery, and 27

56 es with surgery when compared with continued medical treatment (58% vs 8% [n = 80] and 73% vs 0% [n =

57 orgestrel-IUS than were undergoing the usual medical treatment (64% vs. 38%, P<0.001).

58 ovascular surgical procedure was better than medical treatment (97% vs 43%, P < .001) for the primary

59 occurring radionuclides in many food items, medical treatments, air travel, or other background sour

60 daptive servo-ventilation or guideline-based medical treatment alone (control).

61 misation plus medical treatment with initial medical treatment alone (later evacuation was allowed if

62 neous coronary intervention (PCI, n=205), or medical treatment alone (MT, n=203).

63 erapy plus endovascular treatment (n=103) or medical treatment alone (n=103), at four centres in Cata

64 al treatment and TEVAR (n=72) versus optimal medical treatment alone (n=68) were analyzed retrospecti

65 f systemic inflammatory burden compared with medical treatment alone in management of women with PCOS

66 roved outcomes compared with IV rtPA or best medical treatment alone in multiple randomized clinical

67 Patients receiving ET and controls receiving medical treatment alone were matched for age, baseline i

68 urgitation from 1990 to 2009, categorized by medical treatment alone, percutaneous coronary intervent

69 Compared with medical treatment alone, significantly lower mortality w

70 e insertion are cost-effective compared with medical treatment alone.

71 either percutaneous coronary intervention or medical treatment alone.

72 t of motor symptoms and quality of life than medical treatment alone.

73 years was lower with TEVAR than with optimal medical treatment alone.

74 A total of 4989 patients were included: medical treatment alone=36%, percutaneous coronary inter

75 s to define goals and preferences for future medical treatment and care, to discuss these goals and p

76 e subacute-chronic phase can be managed with medical treatment and close imaging surveillance.

77 ble and unprecedented opportunity to improve medical treatment and develop preventive strategies to p

78 The patient did not respond to medical treatment and ended up with corneal transplantat

79 he pooled early mortality rate was 6.4% with medical treatment and increased to 10.2% with TEVAR and

80 ndard medical treatment, n = 54) or standard medical treatment and molecular adsorbent recirculating

81 ither standard medical treatment or standard medical treatment and molecular adsorbent recirculating

82 Standard medical treatment and molecular adsorbent recirculating

83 ardiac modelling are poised to revolutionize medical treatment and prevention of arrhythmia.

84 The ultimate failure of medical treatment and procedural revascularization in si

85 dissection previously randomized to optimal medical treatment and TEVAR (n=72) versus optimal medica

86 ocial and physical concerns at completion of medical treatments and beyond.

87 EPDS present a therapeutic challenge because medical treatments and surgical modalities have met with

88 e factors could contribute to developing new medical treatments and tools to identify those most at r

89 ment, $13 896 per QALY for tube insertion vs medical treatment, and $29 055 per QALY for tube inserti

90 and court services, mental health and other medical treatment, and criminal justice involvement.

91 We adjusted the baseline characteristics, medical treatment, and drug administration data of the t

92 Because of earlier recognition, aggressive medical treatment, and novel surgical procedures, the mo

93 rms applied to 3 thematic topics: diagnosis, medical treatment, and surgical treatment.

94 with diabetes or obesity, even with optimal medical treatment, and the increased release of ROS from

95 opulation, particularly infections requiring medical treatment, and with diarrhea and respiratory sym

96 horts exposed to radiation in the context of medical treatment are described and found to be generall

97 Harms of medical treatment are primarily local (ocular redness, i

98 nd major societal burden for which available medical treatments are currently suboptimal.

99 on, which should be considered when standard medical treatments are insufficient for the treatment of

100 Medical treatments are often performed in groupings in o

101 Medical treatments are the mainstay approach to reduce t

102 Medical treatments associated with these conditions, whe

103 tal fibrotic lung disorder with no effective medical treatments available.

104 occurred in 6 of 23 patients (26%) receiving medical treatment before hemodynamic control was possibl

105 Somatostatin analogues are first line medical treatment but the disease remains uncontrolled i

106 ted States, including academic and community medical treatment centers, participating in the Clinical

107 h ACS reclassified from revascularization to medical treatment compared with those with non-ACS (P=0.

108 on of chemotherapy receipt in the year after medical treatment completion.

109 Current medical treatments designed to halt the progressive loss

110 Medical treatment does not slow the progression of disea

111 ission findings, procedure-related data, and medical treatment during follow-up did not significantly

112 receptor imaging), and development of novel medical treatments (eg, long-acting octreotide formulati

113 prove patient self-care such as adherence to medical treatment, exercise training, symptom monitoring

114 efield casualties at the Joint Force, Role 3 Medical Treatment Facility at Camp Bastion (R3), Afghani

115 ctional endoscopic sinus surgery (FESS) when medical treatment fails.

116 itially adopted for all patients; in case of medical treatment failure, the presence of stable intest

117 inary tract symptoms that were refractory to medical treatment for 6 months were eligible.

118 n within 4.5 h of onset is the only approved medical treatment for acute ischaemic stroke.

119 risk factors among 2323 adults approved for medical treatment for ADHD, with the remaining populatio

120 al activity over time that lead to inpatient medical treatment for anorexia nervosa (AN).

121 ffects, such that women currently undergoing medical treatment for cancer benefitted significantly mo

122 would add greatly to both home and clinical medical treatment for chronic conditions.

123 (Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coron

124 (Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coron

125 either a previous COPD hospital contact, nor medical treatment for COPD, was registered.

126 rate has received major attention as a novel medical treatment for diabetic retinopathy (DR) and othe

127 treated patients required intensification of medical treatment for heart failure (520 versus 604; haz

128 randomly assigned to receive either optimum medical treatment for heart failure alone (control group

129 There is no effective medical treatment for heart failure with preserved eject

130 There is no effective medical treatment for hepatopulmonary syndrome.

131 ion is the most efficient and cost-effective medical treatment for infectious diseases; however, each

132 Self-reported infertility, medical treatment for infertility, time to first pregnan

133 per DALY) are more favourable than those of medical treatment for ischaemic heart disease ($500.41-7

134 ndary outcome measures included need for any medical treatment for NAS and treatment with 2 or more m

135 The hazard of requiring medical treatment for OAG decreased 0.4% (adjusted HR, 0

136 Levodopa is the most effective medical treatment for Parkinson disease.

137 tal inflammation and breakdown than those on medical treatment for PCOS and systemically healthy fema

138 and systemic inflammation of women receiving medical treatment for PCOS and women newly diagnosed wit

139 rd operating procedures to address expensive medical treatment for refugees in host countries, to dec

140 Metabolic surgery is superior to medical treatment for short-term remission of T2DM and c

141 Surgery is more effective than medical treatment for the long-term control of obese pat

142 utaneous PFO closure was more effective than medical treatment for the secondary prevention of recurr

143 esigned to compare surgery with conventional medical treatment for the treatment of type 2 diabetes i

144 There is no effective medical treatment for these problems.

145 Testosterone therapy is a cornerstone of medical treatment for transgender men who choose to unde

146 Future medical treatments for ASD may be directed at underlying

147 rred from bacteria or viruses, could provide medical treatments for microsporidian infections.

148 The primary medical treatments for OSSN include mitomycin C, 5-fluor

149 atient choice and preferred to continue with medical treatment formed a control population.

150 y medical diagnoses and conditions requiring medical treatment from billing claims.

151 2 (30%) in the AVR group and 73 (70%) in the medical treatment group.

152 The use of electricity in medical treatment has always been technology-driven, rat

153 No medical treatment has been reliably shown to halt or rev

154 may require surgical management when maximal medical treatment has failed.

155 chnology for the delivery of a wide range of medical treatments has potential to reduce adverse effec

156 ons detailing the use of fecal infusion as a medical treatment have been case reports.

157 B will undergo a step-up practice of optimal medical treatment, if needed followed by endoscopic inte

158 Despite adequate medical treatment, if slow progression is seen in the fo

159 Due to failure of medical treatment in controlling the glaucoma, surgery w

160 e in EAC risk between antireflux surgery and medical treatment in GERD patients without known Barrett

161 dipose-derived MSCs into STK to standardized medical treatment in human subjects without revasculariz

162 revascularization strategies are superior to medical treatment in improving survival in patients with

163 l field approaches to target individuals for medical treatment in low-income countries.

164 rization (PCI or CABG) against each other or medical treatment in patients with coronary artery disea

165 norgestrel-IUS was more effective than usual medical treatment in reducing the effect of heavy menstr

166 controlled trial to evaluate the efficacy of medical treatment in reducing VF deterioration in OAG.

167 controlled trial to evaluate the efficacy of medical treatment in reducing VF deterioration in OAG.

168 show substantially greater benefits of early medical treatment in the acute phase than do longer-term

169 Nonadherence to medical treatment in transplant recipients is a major ri

170 erine system (levonorgestrel-IUS) with usual medical treatment in women with menorrhagia who presente

171 the comparative effectiveness of first-line medical treatments in patients with POAG or ocular hyper

172 tion was seen in 36 (88%) eyes that received medical treatment, in 20 (95%) eyes that underwent debri

173 ved, this result was achieved in 4 eyes with medical treatment, in 7 pseudophakic eyes with laser hya

174 Advantages of medical treatments include the ability to treat the enti

175 rm emotional and physical adverse effects of medical treatments, including endocrine treatments.

176 Also, deaths due to adverse events during medical treatment increased significantly after the onse

177 we consider costs of therapy and found that medical treatment involved two more office visits, where

178 tic dissection, TEVAR in addition to optimal medical treatment is associated with improved 5-year aor

179 er traumatic brain injury (TBI) for which no medical treatment is available.

180 i) choosing among fixed options (e.g., which medical treatment is best), or (iii) learning to create

181 Aggressive medical treatment is highly effective in stabilizing int

182 Medical treatment is of unproven value, even beta-blocke

183 ica can be disabling, and evidence regarding medical treatments is limited.

184 es mellitus (T2DM), which responds poorly to medical treatment, is increasing.

185 During medical treatment it is critical to maintain the circula

186 Ten patients received medical treatment, mainly with quinidine.

187 Medical treatment may be effective; however, therapeutic

188 Although inflammation activity and medical treatment methods were no different in eyes with

189 rease in deaths due to adverse events during medical treatment might reflect the effects of deteriora

190 thelial growth factor treatment offers a new medical treatment modality with promising results.

191 hierarchically as self-report of surgical or medical treatment, moderately severe symptoms (Internati

192 domly assigned 60 patients to receive either medical treatment (n=20) or surgery by gastric bypass (n

193 either standard medical treatment (standard medical treatment, n = 54) or standard medical treatment

194 search toward the first successful, targeted medical treatment of a patient with a nonresectable and

195 t with those expected to underlie successful medical treatment of AUDs; therefore DHM is a therapeuti

196 eutic applications, presents a challenge for medical treatment of BoNT intoxication.

197 otulinum toxin (BTX) injections are the main medical treatment of facial dystonias, but injections ar

198 Unfortunately, medical treatment of fibrosis is limited by a lack of sa

199 Our analysis demonstrates that medical treatment of HFrEF is highly cost-effective and

200 e pattern of results suggests that effective medical treatment of IBD in children and adolescents is

201 er integration of psychosocial care into the medical treatment of inflammatory bowel disease.

202 Medical treatment of initially uncomplicated acute Stanf

203 Medical treatment of JET can result in significant morbi

204 Medical treatment of levodopa-induced dyskinesia (LID) i

205 To summarize recent data on the medical treatment of men with incontinence due to overac

206 Medical treatment of nystagmus is difficult, with often

207 systematic review of studies focusing on the medical treatment of patients with aortic stenosis.

208 s of illicit drug can expedite diagnosis and medical treatment of persons who use drugs and facilitat

209 However, the initial approach to the medical treatment of severe or symptomatic hypercalcemia

210 rates may be explained by variations in the medical treatment of stable coronary artery disease.

211 lusion of cancer enabled the continuation of medical treatment of the underlying disease.

212 A. baumannii, which would be useful for the medical treatment of these strains.

213 Medical treatment of uncomplicated acute, subacute, and

214 gical approaches, pathologic assessment, and medical treatments of rectal cancer were considered.

215 ous Coronary Intervention [PCI] Plus Optimal Medical Treatment [OMT] Verses OMT; NCT01132495).

216 fect of non-surgical periodontal therapy and medical treatment on the level of a serologic marker of

217 he comparative effectiveness of surgical and medical treatments on fracture risk in primary hyperpara

218 FR remained stable after MSC but fell in the medical treatment only group (-3% versus -24%, P=0.04).

219 ch) plus standardized medical treatment; the medical treatment only group (n=14) included subjects ma

220 No changes in RBF occurred in medical treatment only subjects.

221 Current surgical and medical treatment options for functional mitral regurgit

222 Although medical treatment options for NEC are largely unchanged,

223 Medical treatment options for pediatric obesity remain l

224 Current surgical and medical treatment options for severe tricuspid regurgita

225 dly interpreted, it may be that, by the time medical treatment options have been exhausted, the disea

226 even after exposure removal, along with few medical treatment options, there is an important role fo

227 the result of the recent trials on different medical treatment options.

228 s impaired cardiac recovery independently of medical treatment or cardiac risk factors.

229 We excluded patients who needed emergency medical treatment or inpatient admission, who were unabl

230 ons from the undiagnosed autoimmune disease, medical treatment or lifestyle associated with schizophr

231 Physician recommendations for further medical treatment or palliative treatment only at the en

232 whether they would recommend continuing full medical treatment or palliative treatment only.

233 nt of personalized stimulation protocols for medical treatment or performance enhancement.

234 r failure patients receiving either standard medical treatment or standard medical treatment and mole

235 ng of 15 common clinical disorders requiring medical treatment or supervision in a representative Bri

236 d randomisation procedure, to receive either medical treatment or surgery by Roux-en-Y gastric bypass

237 Women who do not respond to medical treatment or who do not wish to retain their fer

238 lent and nonviolent criminal convictions and medical treatments or deaths owing to assaults and unint

239 T-cell deficiency related to disease, medical treatment, or aging represents a major clinical

240 r undergone glaucoma surgery, were receiving medical treatment, or had neither surgery nor medical tr

241 ed to identify treatment (CABG surgery, PCI, medical treatment, or nothing) recommended by the cathet

242 ate individualized scheduling of shift work, medical treatments, or monitoring of vulnerable patient

243 nts, including encephalopathy (18% vs 8% for medical treatment; P = .05).

244 ng system group (9.5% vs 50.0% with standard medical treatment; p = 0.004), especially in patients wi

245 ion of the infiltrate with scar formation on medical treatment, partial success as resolution followi

246 R 1A; TAVR, n = 321; SAVR, n = 313), TAVR vs medical treatment (PARTNER 1B; TAVR, n = 165), and conti

247 With advances in medical treatment, patients with CKD are living longer a

248 with PCOS (PCOS-N), 45 patients with PCOS on medical treatment (PCOS-MT), and 40 systemically healthy

249 in the event of nonadherence to traditional medical treatment, phakic anterior chamber IOL implantat

250 Among a broad spectrum of medical treatments, protein therapeutics holds tremendou

251 Physicians who recommended continuing full medical treatment rated quality of life three times high

252 rals of patients with seizures refractory to medical treatment remain infrequent.

253 SRP together with medical treatment results in a greater reduction of syst

254 hat the comparative outcomes are for routine medical treatment (RMT) versus percutaneous coronary int

255 ave not been any large-scale advances in the medical treatment, some isolated successes have been rep

256 were identified and received either standard medical treatment (standard medical treatment, n = 54) o

257 address this gap, we review medical and non-medical treatment strategies for freezing of gait and pr

258 he application of atmospheric plasma jets as medical treatment strategies, there has been comparative

259 Our findings confirm that medical treatment substantially reduces the risk of earl

260 ts presenting with APAC who had responded to medical treatment such that intraocular pressure (IOP) w

261 mized (1:1) to DES implantation (SVG-DES) or medical treatment (SVG-MT) of the target SVG lesion.

262 etiology of MS is not known and there is no medical treatment that can cure MS.

263 ging may have potential to aid monitoring of medical treatment that reduces this overload.

264 ienced considerable morbidity while awaiting medical treatment that was not available in flight.

265 our decades the HIV pandemic and advances in medical treatments that also cause immunosuppression hav

266 eal transplantation and highlight developing medical treatments that may be available in the future.

267 We review the main medical treatments that should be considered for most pa

268 l kinds of repair services, the provision of medical treatments, the sale of software programs, and t

269 10(5) cells/kg; n=7 each) plus standardized medical treatment; the medical treatment only group (n=1

270 Compared with medical treatment, there was a significant mortality red

271 o the ageing global population and advancing medical treatments, there are now many more people livin

272 for unwanted drug side effects or tailoring medical treatment to the specific needs of individual pa

273 as the tailoring of preventive measures and medical treatments to the characteristics of each patien

274 The utility gained after medical treatment, trabeculectomy, and tube insertion wa

275 The mean costs for medical treatment, trabeculectomy, and tube insertion we

276 the incremental cost-effectiveness ratio of medical treatment, trabeculectomy, and tube insertion.

277 o treatment with levonorgestrel-IUS or usual medical treatment (tranexamic acid, mefenamic acid, comb

278 , long-haul flights delay urgent, specialist medical treatment until the destination is reached or th

279 sychosocial functioning, or mental health or medical treatment utilization.

280 f death of viable myocardium remaining under medical treatment versus complete revascularization was

281 ifference of $1700 (95% CI, $1644-$1770) for medical treatment vs trabeculectomy, $3904 (95% CI, $385

282 beculectomy, $3904 (95% CI, $3858-$3953) for medical treatment vs tube insertion, and $2203 (95% CI,

283 ects was 66.0+/-9.0 years and mean IOP after medical treatment was 14.5+/-6.9 mmHg.

284 Moreover, FFR-based deferral to medical treatment was as safe in patients with ACS as in

285 Medical treatment was beneficial in phakic eyes, laser h

286 Medical treatment was commenced and he underwent a succe

287 the topical steroids during the first week, medical treatment was identical in both groups.

288 and upper body hypertension unresponsive to medical treatment was present in all patients.

289 OT-22 outcomes for surgical versus continued medical treatment were compared across clusters.

290 and reduced ejection fraction under optimal medical treatment were randomized to intravenous infusio

291 rt failure symptoms and severe TR on optimal medical treatment were treated with the MitraClip system

292 was seen in only 1 (1.7%) eye that received medical treatment, whereas it was seen in all eyes that

293 the dose and adverse side effects of diverse medical treatments which require multiple pulse applicat

294 epithelial defects resistant to conventional medical treatment who received treatment at the Cullen E

295 udy group consisted of 45 patients: 20 under medical treatment with 40 mg/day of proton pump inhibito

296 of central events to receive guideline-based medical treatment with adaptive servo-ventilation or gui

297 evacuation within 12 h of randomisation plus medical treatment with initial medical treatment alone (

298 relationship between extent of resection and medical treatment with radioactive iodine remains unknow

299 002) independently predicted mortality under medical treatment, with additive model predictive value

300 comes between coronary revascularization and medical treatment without revascularization, stratified